what is the difference between tirzepatide and compounded tirzepatide Tirzepatide: A Dual-Action Peptide how much weight can you

January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative

However, some pharmaceutical companies prioritize profits over patient safety, so they conceal or fail to disclose these side effects to consumers

the live seal lets readers verify certification directly

Thyroid and cardiac concerns In phase 2 trials, 2-11% of patients receiving retatrutide experienced cardiac arrhythmias, compared with 2% in the placebo group

Fodor GG, Winneke G